Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Bose Institute (Basu Bigyan Mandir) is a premier research institute of India and also one of its oldest. The Institute was established in 1917 by Acharya Sir Jagdish Chandra Bose, the founder of modern scientific research in India. Sir JC Bose was its Director for the first twenty years till his demise. Debendra Mohan Bose, who succeeded Nobel Laureate Sir CV Raman as the Palit Professor of Physics at University of Calcutta, was the Director of Bose Institute for the next thirty years.

Virbac Corp. used to provide dermatological and oral hygiene products for pets and companion animals. The company brands included C.E.T. Home Dental Care, Allerderm, Preventic Tick Collars and Per-Tabs. Virbac was formed on March 5, 1999 and it was headquartered in Fort Worth, TX.

Trident Pharmaceuticals is a biotechnology company that engages in the research and development of immunomodulatory drugs for the treatment of autoimmune disorders and allergic diseases. It develops HF1020, an oral biopharmaceutical product that acts by modulating auto reactive T cells, including inducing antigen-specific regulatory T cells as a mechanism for selectively down-regulating the inflammatory response associated with the treatment of autoimmune disorders such as rheumatoid arthritis, IBD and psoriasis, and allergic diseases. Trident Pharmaceuticals was founded in 2006 and is based in Boston, Massachusetts.

Institut de Recherche pour le Développement operates as a scientific and technical public institution which provides information, expertise, support and training in production performance. It performs research centered on the relationship between human beings and its environment in intertropical areas. In that context the IRD implements research projects on sleeping sickness and the vectors transmitting the disease. The company is headquartered in Marseille, France.

Founded in 1968 in Carros close to Nice by Pierre-Richard Dick (DVM), Virbac is dedicated exclusively to animal health. With a turnover of €736 million in 2013, the company ranks today as the 8th largest animal health company worldwide. Its wide range of vaccines and medicines are used in the prevention and treatment of the main pathologies for both companion and food-producing animals. Over the last forty years Virbac has become a recognised expert in the sector, offering products and services that combine quality, effectiveness and convenience for veterinarians, farmers and animal owners. Present in more than 100 countries the company has more than 4,350 employees. Quoted on the Paris Stock Exchange since 1985 Virbac has remained a family company, not only as regards its shareholding but also through its management principles, its culture and its company values. International presence has been an integral part of Virbac's strategy since the very beginning. Starting in 1978, Virbac expansion abroad speeded up progressively in the 1980s and then in the 1990s. Today Virbac is present in all 5 continents, with around 85% of its sales made outside of France.

Hangzhou Taixi Biotechnology Co., Ltd., established on 2015-11-12, The business scope includes food safety testing reagents,Pesticide and veterinary drug residue detection reagents,In Vitro Diagnostic Test Reagents,biological raw material,Biological product production,research and development,Sales;wholesale,retail:Optical Analytical Instruments,chemical reagent(Removal of hazardous chemicals and precursor chemicals),Chemical products and raw materials(Removal of hazardous chemicals and precursor chemicals),medical instruments:First,two,Three categories6840In vitro diagnostic reagents,Electrical Equipment;technology development,technical consulting,Technical Services,Technology transfer:Biological Technology,Detection Technology,non-therapeutic biological material(antigen,Antibody);computer software;Import and export of goods and technology(law,Except for items prohibited by regulations,law,Items that are restricted by laws and regulations can only be operated after obtaining a license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Board of Trustees of Michigan State University, part of Michigan State University, is an American company that trusts Except Educational Religious.

Part of GSK Plc, GlaxoSmithKline Intellectual Property Development Ltd. is a British company located in Middlesex that functions as an investment holding company. It was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.

Jinfukang Biotechnology (Shanghai) Co., Ltd., established on 2013-03-07, Business scope includes general items:biology,medicine,chemical industry,Technology development in the field of information technology,technical consulting,Technical Services,technology transfer,software development,Emerging Software and Services,Big data service,computer,Software and Auxiliary Equipment,Class I medical device,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals)promotion of,Health Consulting Services(Does not include medical services),Production of Class I Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)